Evidence map›Paper›PMID 38789815›Full record

ReviewAntonie van Leeuwenhoek2024

Biotechnological potential of actinomycetes in the 21st century: a brief review.

Rafael de Souza Rodrigues, Antonia Queiroz Lima de Souza, Maria Divina Oliveira Feitoza, Thalita Caroline Lima Alves, Anderson Nogueira Barbosa, Sarah Raquel Silveira da Silva Santiago, Afonso Duarte Leão de Souza

Abstract readReview
PubMed Publisher
In one paragraph

Review in Antonie van Leeuwenhoek, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Draft genome sequence of the meloxicam-degradingMicrobiology resource announcements · 2025
    Article
  7. Assessing hydrocarbon degradation capacity ofFrontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rafael de Souza RodriguesPrograma de Pós-Graduação em Biodiversidade e Biotecnologia, Universidade Federal do Amazonas, Manaus, Amazonas, Brazil. rafaelsr.bio@gmail.com.
Antonia Queiroz Lima de SouzaPrograma de Pós-Graduação em Biodiversidade e Biotecnologia, Universidade Federal do Amazonas, Manaus, Amazonas, Brazil.
Maria Divina Oliveira FeitozaInstituto de Saúde e Biotecnologia, Universidade Federal do Amazonas, Coari, Amazonas, Brazil.
Thalita Caroline Lima AlvesFaculdade de Ciências Agrárias, Universidade Federal do Amazonas, Manaus, Amazonas, Brazil.
Anderson Nogueira BarbosaCentral Analítica, Centro de Apoio Multidisciplinar, Universidade Federal do Amazonas, Av. General Rodrigo Octavio Jordão Ramos, 6200, Coroado I, Manaus, Amazonas, CEP 69.077-000, Brazil.
Sarah Raquel Silveira da Silva SantiagoCentral Analítica, Centro de Apoio Multidisciplinar, Universidade Federal do Amazonas, Av. General Rodrigo Octavio Jordão Ramos, 6200, Coroado I, Manaus, Amazonas, CEP 69.077-000, Brazil.
Afonso Duarte Leão de SouzaPrograma de Pós-Graduação em Biodiversidade e Biotecnologia, Universidade Federal do Amazonas, Manaus, Amazonas, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This brief review aims to draw attention to the biotechnological potential of actinomycetes. Their main uses as sources of antibiotics and in agriculture would be enough not to neglect them; however, as we will see, their biotechnological application is much broader. Far from intending to exhaust this issue, we present a short survey of the research involving actinomycetes and their applications published in the last 23 years. We highlight a perspective for the discovery of new active ingredients or new applications for the known metabolites of these microorganisms that, for approximately 80 years, since the discovery of streptomycin, have been the main source of antibiotics. Based on the collected data, we organize the text to show how the cosmopolitanism of actinomycetes and the evolutionary biotic and abiotic ecological relationships of actinomycetes translate into the expression of metabolites in the environment and the richness of biosynthetic gene clusters, many of which remain silenced in traditional laboratory cultures. We also present the main strategies used in the twenty-first century to promote the expression of these silenced genes and obtain new secondary metabolites from known or new strains. Many of these metabolites have biological activities relevant to medicine, agriculture, and biotechnology industries, including candidates for new drugs or drug models against infectious and non-infectious diseases. Below, we present significant examples of the antimicrobial spectrum of actinomycetes, which is the most commonly investigated and best known, as well as their non-antimicrobial spectrum, which is becoming better known and increasingly explored.

Indexed as

ActinobacteriaBiotechnologyAnti-Bacterial AgentsSecondary MetabolismAnti-Bacterial AgentsActinomycetesBioactive metabolitesBiotechnological perspectiveNew applications

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.